“I think it’s the most exciting period in cancer discovery and development that I’ve experienced over the last 25 years,” says Susan Galbraith, executive vice president of oncology R&D at AstraZeneca. Galbraith joins Bloomberg Intelligence analyst Sam Fazeli fresh from the ASCO conference to unpack how ctDNA, earlier intervention and next-generation oncology platforms could reshape cancer care. They discuss AstraZeneca’s Stride regimen in liver cancer, Serena-6 in breast cancer, progress in pancreatic cancer and the company’s push across ADCs, bispecifics, CAR-T and radio conjugates.

&ldquo;I think it&rsquo;s the most exciting period in cancer discovery and development that I&rsquo;ve experienced over the last 25 years,&rdquo; says Susan Galbraith, executive vice president of oncology R&amp;D at AstraZeneca. Galbraith joins Bloomberg Intelligence analyst Sam Fazeli fresh from the ASCO conference to unpack how ctDNA, earlier intervention and next-generation oncology platforms could reshape cancer care. They discuss AstraZeneca&rsquo;s Stride regimen in liver cancer, Serena-6 in breast cancer, progress in pancreatic cancer and the company&rsquo;s push across ADCs, bispecifics, CAR-T and radio conjugates.

Vanguards of Healthcare is a series of exclusive conversations with management teams and thought leaders discussing changes on the forefront of the industry, including innovations in medical products and technologies, advances in clinical research, new service models, wellness and regulations.

Vanguards of Healthcare is a series of exclusive conversations with management teams and thought leaders discussing changes on the forefront of the industry, including innovations in medical products and technologies, advances in clinical research, new service models, wellness and regulations.

Vanguards of Healthcare by Bloomberg Intelligence

AstraZeneca’s ASCO Readout on Oncology’s Next Wave

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/70f50f64-3628-4245-985d-b46400d36ead/transcript

“If you plan, the cases can go much more smoothly. And if you have patient-specific instrumentation, they can go much more quickly” says restor3D’s CEO Kurt Jacobus in this episode of Vanguards of Healthcare. He sat down with BI analyst Matt Henriksson to elaborate on personalized orthopedic implants, outlining how the win then for the surgeon is the capacity to complete more cases, with better patient outcomes reputationally, and the win for the facility is getting another case into the operating room. 

The in-depth interview covered restor3D’s AI planning and 3D printing capabilities, its path in integrating the Conformis acquisition to allow it to compete against larger companies in the knee-replacement market and the upcoming launch of its patient app. He also discussed how his drive to use technology to solve problems led him from the consulting world to leading medtech companies.

Listen to this episode on Apple Podcasts and Spotify.

 

&ldquo;If you plan, the cases can go much more smoothly. And if you have patient-specific instrumentation, they can go much more quickly&rdquo; says restor3D&rsquo;s CEO Kurt Jacobus in this episode of Vanguards of Healthcare. He sat down with BI analyst Matt Henriksson to elaborate on personalized orthopedic implants, outlining how the win then for the surgeon is the capacity to complete more cases, with better patient outcomes reputationally, and the win for the facility is getting another case into the operating room.&nbsp;
The in-depth interview covered restor3D&rsquo;s AI planning and 3D printing capabilities, its path in integrating the Conformis acquisition to allow it to compete against larger companies in the knee-replacement market and the upcoming launch of its patient app. He also discussed how his drive to use technology to solve problems led him from the consulting world to leading medtech companies.
Listen to this episode on Apple Podcasts and Spotify.
&nbsp;

Restor3D Combines AI with 3D Printing to Create Personalized Ortho Solutions

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/3c93757f-71f8-4b41-8406-b46600c1e294/transcript

“Forty percent of patients in this country alone in the first year drop out [of current retinal disease treatments] and every one of those patients ends up going blind. By far the most expensive disease in the world is blindness and the reason for that is really quite simple. It’s because the mortality doesn’t change, the use of resources skyrockets, but the mortality doesn’t change. In this country, every blind patient costs over $66,000 a year,” says Pravin Dugel, CEO of Ocular Therapeutix. “If we reduce that dropout rate by even 10% with Axpaxli, and I’m sure we’ll do even better, we’re talking about a quarter million fewer patients in this country alone who will not go blind. The impact of that, not just on a human basis but on an economic basis, is astronomical.” In this episode of the Vanguards of Healthcare podcast, Pravin sits down with Bloomberg Intelligence senior analyst Ann-Hunter van Kirk to discuss how the company can reduce the therapeutic and economic burden of retinal diseases.

&ldquo;Forty percent of patients in this country alone in the first year drop out [of current retinal disease treatments] and every one of those patients ends up going blind. By far the most expensive disease in the world is blindness and the reason for that is really quite simple. It&rsquo;s because the mortality doesn&rsquo;t change, the use of resources skyrockets, but the mortality doesn&rsquo;t change. In this country, every blind patient costs over $66,000 a year,&rdquo; says Pravin Dugel, CEO of Ocular Therapeutix. &ldquo;If we reduce that dropout rate by even 10% with Axpaxli, and I&rsquo;m sure we&rsquo;ll do even better, we&rsquo;re talking about a quarter million fewer patients in this country alone who will not go blind. The impact of that, not just on a human basis but on an economic basis, is astronomical.&rdquo; In this episode of the Vanguards of Healthcare podcast, Pravin sits down with Bloomberg Intelligence senior analyst Ann-Hunter van Kirk to discuss how the company can reduce the therapeutic and economic burden of retinal diseases.

Ocular Therapeutix Cuts Blindness Toll

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/4331a593-4e34-4348-9d55-b45800bff63a/transcript

“We’re seeing it already to much more of a preventative proactive monitoring to find these things earlier in the patient journeys and help eliminate and prevent and reduce downstream costs,” IRhythm Technologies CEO Quentin Blackford discusses the opportunities of remote monitoring with Bloomberg Intelligence. In this Vanguards of Healthcare podcast episode, Blackford sits down with BI analyst Matt Henriksson for an in-depth interview on iRhythm, how its Zio monitoring platform provides an end-to-end solution to monitor patients without disrupting their everyday lives, and its strategy to expand into the primary care setting to provide a more proactive approach to detect cardiac arrhythmias and other health signals.

Listen to this episode on Apple Podcasts and Spotify.

&ldquo;We&rsquo;re seeing it already to much more of a preventative proactive monitoring to find these things earlier in the patient journeys and help eliminate and prevent and reduce downstream costs,&rdquo; IRhythm Technologies CEO Quentin Blackford discusses the opportunities of remote monitoring with Bloomberg Intelligence. In this Vanguards of Healthcare podcast episode, Blackford sits down with BI analyst Matt Henriksson for an in-depth interview on iRhythm, how its Zio monitoring platform provides an end-to-end solution to monitor patients without disrupting their everyday lives, and its strategy to expand into the primary care setting to provide a more proactive approach to detect cardiac arrhythmias and other health signals.
Listen to this episode on Apple Podcasts and Spotify.

IRhythm Pushes a Proactive Approach to Monitoring

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/7a327caf-80db-4bc1-bda7-b45100b4f237/transcript

AstraZeneca’s ASCO Readout on Oncology’s Next Wave

In 1 playlist(s)

Vanguards of Healthcare by Bloomberg Intelligence

Social links

Follow podcast

Recent clips